ArticleHealth and quality of life outcomes2025
Comparison of the measurement properties of EQ-5D-5L and SF-6Dv2 in Chinese patients on dialysis.
Article in Health and quality of life outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Validation of the Standardized Outcomes in Nephrology - Life Participation (SONG-LP) Instrument in People Receiving Dialysis.Kidney international reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasuring health-related quality of life (HRQoL) in dialysis patients is essential for clinical assessment and economic evaluation. Despite the emergence and increasing use of updated instruments, evidence comparing their performance in Chinese dialysis patients remains limited. The aim of this study was to compare the measurement properties of the EQ-5D-5L and the SF-6Dv2 instruments in Chinese patients on dialysis and to provide a reference for future utility scale choice for Chinese dialysis patients.
methodsData were obtained using Wen Juan Xing questionnaire from dialysis patients during November 2023 to January 2024 in hospitals in China. The questionnaire included the EQ-5D-5L, SF-6Dv2, the kidney disease quality of life instrument (KDQOL-36), clinical and socio-demographic characteristics. The agreement of utility scores was assessed using intra class correlation coefficients (ICC) and Bland-Altman plots. The construct validity was evaluated using Spearman's correlation coefficient. The known group validity was evaluated by comparing the scores among patients with different health states, and sensitivity was compared using relative efficiency and the effect size.
resultsA total of 378 patients (male, 49.5%; mean age, 49.1 years) were included in this study. The ICC between EQ-5D-5L and SF-6Dv2 utility values was 0.639. The correlation between the two scales was strong (0.767). Both scales showed known groups validity, although the SF-6Dv2 was more sensitive. The differences in the SF-6Dv2 scores for patients in better and worse health state were greater than those measured by the EQ-5D-5L scores.
conclusionsBoth EQ-5D-5L and SF-6Dv2 instruments are valid for dialysis patients. However, the two scales cannot be used interchangeably, and it appears that the SF-6Dv2 was more sensitive in capturing health state differences for dialysis patients in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.